HEALTH TECHNOLOGY

Veranex Expands European MedTech Capabilities With Acquisition of Medidee

Veranex and Medidee Services | September 21, 2022 | Read time : 02:00 min

Veranex Expands

Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry, announced that it has acquired Medidee, a top MedTech consultancy company headquartered in Lausanne, Switzerland. As a trusted European regulatory and quality service consultancy joining Veranex, Medidee expands and strengthens regulatory affairs, clinical development, and quality assurance services and capabilities for MedTech companies across Europe and the world. This improved ability to navigate the European Union’s Medical Device and In Vitro Diagnostic Device Regulations challenges supports truly full-service MedTech product development and commercialization.

Our acquisition of Medidee significantly expands our European footprint while also materially expanding the scale and scope of the clinical studies we can manage. The combined organization offers offices and expertise across Europe, the U.S., and Asia, augmenting our ability to help MedTech innovators achieve FDA and CE Mark approvals and uninterrupted market access for new as well as proven medical technologies that advance patient care.”

Veranex CEO David Dockhorn

With Medidee’s 11 locations across Europe, India, and Asia-Pacific, and Veranex’s 13 locations across the U.S., Europe, and China, the company now has unprecedented reach to serve clients with a full spectrum of integrated concept-to-commercialization services — design, engineering, regulatory, quality, preclinical research, clinical development, clinical operations, commercial strategy, and market access services — all under one umbrella. Medidee is one of the Top 3 medical device consultancy service providers in Europe uniquely positioned as a leader in future key areas such as digital health, machine learning, and cybersecurity. The company also brings expertise in clinical research exclusively focused on medical devices and in vitro diagnostics.

“Medidee has a proven track record serving regulatory, clinical, and quality needs for companies of all sizes, with consulting expertise and clinical trial support in increasingly diverse therapeutic areas and technology categories across multiple geographies,” shared Medidee co-founders Kim Rochat, Philippe Etter, and Michael Maier. “With these services, coupled with the global infrastructure of Veranex, we expand expertise and resources for the benefit of our clients as well as for all EU innovative manufacturers wishing to access rapidly and efficiently the U.S. market and beyond. We look forward to providing these additional strengths and capabilities,” added the co-founders who take on new roles in the combined organization.

About Veranex
Veranex is the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry. Offering expert guidance from concept to commercialization and across the development continuum, Veranex enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment. At every stage, Veranex customers realize efficiencies in cost and time, while its comprehensive solutions unify and streamline the entire development process. Veranex is backed by Summit Partners, Accelmed, and Lauxera Capital Partners. 

About Medidee Services
With sites in Switzerland, Germany, Denmark, Belgium, Spain, USA, and APAC, Medidee is a global services supplier serving companies ranging from academic startups to majors.

Medidee was established by three partners, all experts in the field of medical devices. With 50 experts in all fields necessary to ensure compliance with the most stringent requirements, Medidee provides the necessary competencies to ensure and demonstrate compliance with all key medical device regulations. Medidee expends regularly to provide the best resources and competencies and supports more than 350 manufactures all over the world.

Spotlight

A visual presentation of information in the form of a chart, graph, or other image accompanied by minimal text, intended to give an easily understood overview, often of a complex subject. Feel free to share these infographics. Focus for Health strives to educate the public, medical professionals, and government of the connection between harmful environmental exposures and chronic illness, as well as how to minimize exposures and maximize health. In doing so, FFH supports the right of every individual to make educated health decisions based on informed consent.

Spotlight

A visual presentation of information in the form of a chart, graph, or other image accompanied by minimal text, intended to give an easily understood overview, often of a complex subject. Feel free to share these infographics. Focus for Health strives to educate the public, medical professionals, and government of the connection between harmful environmental exposures and chronic illness, as well as how to minimize exposures and maximize health. In doing so, FFH supports the right of every individual to make educated health decisions based on informed consent.

Related News

HEALTH TECHNOLOGY

Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial

Novartis Pharma AG | September 19, 2022

Sandoz, a global leader in off-patent medicines, announces further progress on its biosimilar pipeline, with the release of positive results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab. “Biosimilars have the opportunity to create a substantial positive impact on patient access and healthcare systems sustainability. Therefore, this important milestone means that we are one step closer to giving individuals living with osteoporosis access to a more affordable, biosimilar version of this critical medicine, which may help to change the course of their disease.” Florian Bieber, Global Head of Development, Sandoz Biopharmaceuticals Denosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, in men at increased risk of fractures, treatment-induced bone loss, prevention of skeletal related complications in cancer that has spread to the bone, and giant cell tumor of the bone2,3,4,5. The results from the integrated Phase I/III study confirm the biosimilar matches the reference medicine in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in the respective indications; and contributes to demonstration of similarity, which is the basis for use in all indications. Approximately 500 million men and women worldwide may be affected by osteoporosis1, which causes 8.9 million fractures annually – or one fracture every three seconds1. By 2050, hip fractures are projected to increase by 240% in women and 310% in men compared to 19901. The results come soon after Sandoz confirmed acceptance of license applications for two other proposed biosimilars. In July 2022, the application for the first-of-a-kind multiple sclerosis proposed biosimilar natalizumab was accepted for review by the US Food and Drug Administration (FDA) and European Medicines Agency. In June 2022, the EMA and FDA accepted for review Sandoz applications for the high-concentration formulation 100 mg/mL (HCF) of its biosimilar adalimumab. Sandoz biosimilars help patients, in areas including immunology, oncology, nephrology, supportive care and endocrinology, access critical and potentially life-changing medicines sustainably and affordably. Sandoz has a leading global portfolio with eight marketed biosimilars and a further 15-plus in various stages of development. About ROSALIA6 In ROSALIA, 527 postmenopausal women with osteoporosis were randomized to receive either biosimilar denosumab or the reference medicine for up to 78 weeks of treatment. Objectives were to demonstrate similar efficacy in terms of change in lumbar spine bone mineral density, as well as similar pharmacokinetics and pharmacodynamics. The global clinical program for biosimilar denosumab was developed in consultation with major regulatory agencies and the results from this clinical study are expected to support regulatory approval. About denosumab Denosumab is a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone tissue)2. By binding to and inhibiting RANKL, denosumab decreases the production and activity of osteoclasts, resulting in a reduction of bone loss, and subsequently the likelihood of fractures and other serious bone conditions2.

Read More

HEALTHTECH SECURITY

Henry Ford Health and the PINC AI™ Applied Sciences Team Lead Action to Advance Health Equity

Henry Ford Health | November 21, 2022

Henry Ford Innovations one of the nation's leading healthcare innovation programs, recently hosted the inaugural "Advancing Health Equity Through Innovation and Collaboration" event in partnership with the PINC AI™ Applied Sciences team, a leading provider of advanced analytics, technology solutions and clinical research support services to the life sciences industry. The initiative's purpose was to turn health equity conversations into action by taking measurable steps towards improving the health of millions. Participants included global leaders in life sciences, as well as Henry Ford Health innovators who are already implementing programs to address health disparities in groups who have been historically marginalized and underrepresented. "Part of innovating is looking for partners to expand successful test programs and develop new ones. Partnerships like the ones we're forging with these corporate partners will create a true impact in addressing health equity. We are thrilled to have the opportunity to share our findings with national leaders in the life sciences and pharmaceutical industries and chart a path forward to bring these solutions to help more people." Lisa Prasad, Henry Ford Health's Chief Innovation Officer and leader of Henry Ford Innovations The two-day event in late October included a presentation of case studies from successful Henry Ford Health programs, including community-based partnerships to increase health screenings. That program found that a lack of trust in institutions can deter people from getting preventative care and that using community partners for healthcare services can reduce barriers and increase access to care. Other case studies covered programs to improve hypertension in young African American men and reduce infant mortality among underserved populations. The unique action-focused event allowed leaders from Henry Ford Health, the PINC AI™ Applied Sciences team and collaborators from eight global life sciences companies to meet, connect and work together on ways to amplify and expand pilot programs. "The impactful work Henry Ford Health already has under way makes Detroit an ideal location to look for solutions to reduce health inequities across the country," said Denise Juliano, Life Sciences Group Vice President, PINC AI™ Applied Sciences. "PINC AI™ Applied Sciences partners with leaders in healthcare to improve health outcomes and advance equitable care for all people. This initiative was a great step forward to accelerate our efforts to address the challenges of health inequities that continue to persist." Because of Henry Ford Health's community connections and its long-standing work to improve diversity, equity, inclusion and justice (DEIJ), the health system is a leader in researching and tackling health disparities in Detroit. In 2021, Henry Ford launched a new initiative to improve the representation of African American people in cancer clinical trials. It was an important collaboration, especially considering that recent research shows 85 percent of participants in clinical trials are white. Another program supported by HFI provides medical mentorship and internship opportunities for Detroit-based high school students. Both initiatives serve as examples of the meaningful change health and life sciences organizations can affect together. "This initiative is an example of how Henry Ford's commitment to DEIJ extends beyond ideas and connects directly to action," said Ikenna Okereke, M.D., Henry Ford Health's Vice Chair of Surgery and Director of Thoracic Surgery. "Through Henry Ford's Department of Surgery High School Mentorship Program, I've seen firsthand how programs that work in other communities can grow for a larger impact. I'm excited to be a part of the next chapter in creating more programs and initiatives to address health disparities." Henry Ford Health and the PINC AI™ Applied Sciences team will now work with the summit's participating partners to strengthen and scale solutions to advance health equity. About Henry Ford Health Serving communities across Michigan and beyond, Henry Ford Health is committed to partnering with patients and members along their entire health journey. Henry Ford Health provides a full continuum of services – from primary and preventative care, to complex and specialty care, health insurance, a full suite of home health offerings, virtual care, pharmacy, eye care and other healthcare retail. It is one of the nation's leading academic medical centers, recognized for clinical excellence in cancer care, cardiology and cardiovascular surgery, neurology and neurosurgery, orthopedics and sports medicine, and multi-organ transplants. Consistently ranked among the top five National Institutes of Health (NIH)-funded institutions in Michigan, Henry Ford Health engages in more than 2,000 research projects annually. Equally committed to educating the next generation of health professionals, Henry Ford Health trains more than 4,000 medical students, residents, and fellows every year across 50+ accredited programs. With more than 33,000 valued team members, Henry Ford Health is also among Michigan's largest and most diverse employers, including nearly 6,000 physicians and researchers from the Henry Ford Medical Group, Henry Ford Physician Network and Jackson Health Network. The health system is led by President and CEO Robert G. Riney and serves a growing number of customers across 250+ locations throughout Michigan including five acute care hospitals, two destination facilities for complex cancer and orthopedics and sports medicine care, three behavioral health facilities, primary care and urgent care centers. About the PINC AI™ Platform PINC AI™ is the technology and services platform of Premier Inc. With more than 20 years' worth of cost, quality and operational data gleaned from 45 percent of U.S. hospital discharges, 812 million hospital outpatient and clinic encounters and 131 million physician office visits, the PINC AI™ platform provides actionable intelligence to help improve outcomes, support improved financial performance and enable success in new, alternative payment models. PINC AI™ offerings rely on advanced analytics to identify improvement opportunities, consulting services for clinical and operational design, and workflow solutions to hardwire sustainable change. The PINC AI™ platform is also the data engine powering Premier's newest brands – Remitra™ and Contigo Health®.

Read More

HEALTH TECHNOLOGY

Pure Health UAE Largest Healthcare Platform Signs a Deal With Equity Group Investments to Invest Half a Billion Dollars in a U.S. Healthcare Company

Pure Health | September 05, 2022

Alpha Dhabi Holding subsidiary, Pure Health, the largest integrated healthcare platform of the United Arab Emirates announced that it has entered into a definitive purchase agreement to acquire a minority equity investment in Ardent Health Services a leading U.S. healthcare provider based in Nashville, Tennessee, for a total investment of $500 million. The investment is subject to customary closing conditions and will be finalized after receipt of all necessary U.S. regulatory approvals. Ardent is the fourth largest privately held acute care hospital operator in the U.S., with 30 hospitals and more than 200 sites of care across six states, and approximately 26,000 employees. Pure Health would achieve a minority equity investment by purchasing an interest in Ardent from Equity Group Investments a Chicago-based private investment firm and majority owner of Ardent. As part of its investment, Pure Health would receive board observer rights but would not have a seat on Ardent’s board of directors. The investment does not include plans for either the expansion of Ardent’s physical footprint or collaboration between Ardent and Pure Health in the delivery of care. Equity Group Investments hosted a signing ceremony, which included Farhan Malik, CEO of Pure Health, Sam Zell, founder and chairman of EGI, and Marty Bonick, president and chief executive officer of Ardent. “One of EGI’s strengths is partnering with like-minded individuals with the experience and passion for how we approach investment opportunities. We look forward to developing a productive relationship with Pure Health as they continue to explore the various dynamics of the U.S. healthcare system,” Sam Zell Commenting on the major investment announcement, Farhan Malik said, “This landmark investment agreement marks a quantum leap for the UAE and the global healthcare industry.” “This is an exciting opportunity for Pure Health, as we continue to build relationships with leading U.S. healthcare providers to leverage the highest standards and best clinical practices to provide an unrivalled healthcare experience for patients in the UAE,” said Malik. “Ardent has a strong track record of delivering outstanding services across the United States, and we look forward to gaining additional knowledge to support our north star of advancing the science of longevity and unlocking time for humanity.” ABOUT PURE HEALTH Pure Health is an integrated healthcare solutions platform with a diversified portfolio of over 25 hospitals and more than 100 clinics offering 200+ specialties covering services from tertiary care to primary care; health insurance that covers over 2.5 million members; group procurement organization; over 150 laboratories; diagnostics services; rehab services; long term care; medical supplies; and health technology services. With more than 50 million annual clinical encounters and over 25,000 employee strength, the company provides healthcare services across the entire continuum of care. Pure Health is committed to enhancing longevity and helping people live longer, happier, and healthier lives. The company’s centers of excellence bring together clinical knowledge, process expertise, technology, and analytics to deliver outcome-focused, world-class quality across all channels of healthcare with a mandate to future-proof the healthcare system for a world of technological singularity. ABOUT EQUITY GROUP INVESTMENTS Equity Group Investments (EGI), founded by Sam Zell more than 50 years ago, has a long track record of building public and private businesses, including the origination and growth of multi-billion-dollar companies. EGI’s flexible capital and open investment mandate enable the firm to pursue opportunistic transactions across industries and geographies, throughout the capital structure, at any point in the economic cycle. EGI’s current portfolio includes investments in transportation and logistics, health care, manufacturing, agribusiness, energy, retail, waste and infrastructure, and real estate. ABOUT ARDENT HEALTH SERVICES Ardent Health Services invests in people, technology and communities. Through its subsidiaries, Ardent owns and operates 30 hospitals and more than 200 sites of care in six states with approximately 26,000 employees, including 1,200+ employed providers. With a focus on evidence-based practices to improve quality care and patient outcomes, four Ardent hospitals were named to Leapfrog’s Top Hospitals in 2021, and eight Ardent hospitals received a Leapfrog Hospital Safety Grade of A for Spring 2022. Based in Nashville, Tennessee, Ardent is owned by current and former members of Ardent’s management team; Equity Group Investments (EGI), a Chicago-based private investment firm; and Ventas, Inc.

Read More